Related Experiment Video
Updated: Dec 28, 2025

Analysis of Beta-cell Function Using Single-cell Resolution Calcium Imaging in Zebrafish Islets
Published on: July 3, 2018
A Phenotypic Screen Identifies Calcium Overload as a Key Mechanism of β-Cell Glucolipotoxicity
Jennifer Vogel1, Jianning Yin2, Liansheng Su2
1Gilead, Foster City, CA.
Abstract:
Type 2 diabetes (T2D) is caused by loss of pancreatic β-cell mass and failure of the remaining β-cells to deliver sufficient insulin to meet demand. β-Cell glucolipotoxicity (GLT), which refers to combined, deleterious effects of elevated glucose and fatty acid levels on β-cell function and survival, contributes to T2D-associated β-cell failure. Drugs and mechanisms that protect β-cells from GLT stress could potentially improve metabolic control in patients with T2D. In a phenotypic screen seeking low-molecular-weight compounds that protected β-cells from GLT, we identified compound A that selectively blocked GLT-induced apoptosis in rat insulinoma cells. Compound A and its optimized analogs also improved viability and function in primary rat and human islets under GLT. We discovered that compound A analogs decreased GLT-induced cytosolic calcium influx in islet cells, and all measured β-cell-protective effects correlated with this activity. Further studies revealed that the active compound from this series largely reversed GLT-induced global transcriptional changes. Our results suggest that taming cytosolic calcium overload in pancreatic islets can improve β-cell survival and function under GLT stress and thus could be an effective strategy for T2D treatment.
Insights
Protecting pancreatic beta cells from glucolipotoxicity (GLT) is key for type 2 diabetes (T2D) treatment. Compounds that reduce calcium influx protect beta cells from GLT stress, offering a potential T2D therapy.
Area of Science:
- Endocrinology
- Cell Biology
- Pharmacology
Background:
- Type 2 diabetes (T2D) involves pancreatic beta-cell failure due to loss of mass and function.
- Beta-cell glucolipotoxicity (GLT), caused by high glucose and fatty acids, significantly contributes to T2D pathogenesis.
- Identifying compounds that protect beta cells from GLT stress is crucial for developing new T2D treatments.
Purpose of the Study:
- To discover low-molecular-weight compounds that protect pancreatic beta cells from GLT-induced apoptosis.
- To investigate the mechanism by which these compounds exert their protective effects.
- To evaluate the therapeutic potential of these compounds for T2D.
Main Methods:
- Phenotypic screening of compounds for beta-cell protection against GLT.
- Assessment of compound effects on apoptosis, viability, and function in rat insulinoma cells and primary rat/human islets.
- Measurement of cytosolic calcium influx and global transcriptional changes in islet cells.
Main Results:
- Compound A was identified, selectively blocking GLT-induced apoptosis in beta cells.
- Compound A analogs improved beta-cell viability and function under GLT conditions.
- The protective effects correlated with reduced cytosolic calcium influx and reversed GLT-induced transcriptional changes.
Conclusions:
- Reducing cytosolic calcium overload in pancreatic islets is a viable strategy to enhance beta-cell survival and function under GLT stress.
- Compounds targeting calcium influx show promise as a novel therapeutic approach for type 2 diabetes.
- This research provides a mechanistic basis for developing new drugs to combat T2D.
Related Concept Videos
Insulin Secretory Vesicles
Glucose Homeostasis: Pancreatic Islets and Insulin Secretion
Insulin and C-peptide are...
Glucose Transporters
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:
Genetic Screens
Forward genetic screens
Forward or “classical” genetic screens involve creating random mutations in an organism’s DNA using radiation, mutagens, or insertion of additional bases, which...
Diabetes: Symptoms, Diagnosis, and Complications
Diabetes Mellitus: Type 2 and Gestational

